MedCap Q4 2024: A tale of euphoria and despair - Redeye

Redeye updates its estimates and valuation following MedCap releasing its Q4 2024 report. After the share’s nosedive, we believe it has returned to interesting territory. We judge the share’s recent crash also illustrated how high expectations leave little margin for error. While multiples might not recover quickly, we believe there are reasons to be optimistic.

Länk till analysen i sin helhet: https://www.redeye.se/research/1072026/medcap-q4-2024-a-tale-of-euphoria-and-despair?utm_source=finwire&utm_medium=RSS